Blood Test

Could a ‘Universal’ Blood Test for Cancer Be on the Horizon?

Body.Disease.Cancer3When it comes to saving lives from cancer, the earlier the diagnosis, the better. But early diagnosis or identification of certain cancers – including melanoma, colon cancer and lung cancer – is often quite difficult. Now, researchers in the UK have developed a simple blood test that could identify which patients have cancer.

The researchers say their test could help doctors in ruling out cancer for patients who present with certain symptoms, which could save time and money, and help to avoid unnecessary invasive procedures, including colonoscopies and biopsies. Additionally, the test could help with patients who are suspected of having a cancer that is difficult to diagnose.

The test, called the Lymphocyte Genome Sensitivity (LGS) test, examines white blood cells and measures the damage done to their DNA when blasted with different levels of ultraviolet light (UVA). The team explains this type of light damages DNA.

“White blood cells are part of the body’s natural defense system,” says lead researcher Prof. Diana Anderson, from the university’s School of Life Sciences.

“We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light,” she adds. “We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA – the genome – in a cell.”

Overall, the team says their results show a clear difference in the damage to the white blood cells of patients with cancer, patients with pre-cancerous conditions and those who are healthy.

“This is just in its early stages,” said Prof. Anderson, “but it shows a lot of promise.”

Read the full story.

Source: Medical News Today

Quick, Simple Blood Test For Solid Cancers Looks Feasible

Body.Disease.Cancer4The idea of a general, quick and simple blood test for a diverse range of cancers just came closer to reality with news of a new study published in Nature Medicine. Researchers from Stanford University School of Medicine have devised an ultra-sensitive method for finding DNA from cancer tumors in the bloodstream.

Their new test identified around half of patients with stage 1 lung cancer and all patients with stage 2 or higher disease. They also showed the circulation tumor DNA was highly correlated with tumor volume estimated using CT and PET scans.

This suggests an approach based on the new test could monitor tumors at a fraction of the cost of present methods that rely on imaging studies.

Check the full article.

Source: Medical News Today.